[
  {
    "ts": null,
    "headline": "Stocks to Watch Recap: TSMC, United Airlines, GE Aerospace, Lucid",
    "summary": "↗️ TSMC (TSM): The world's largest contract chip maker delivered a record profit last quarter and said it was speeding up its expansion in Arizona. Its American depositary receipts rallied 4% Thursday afternoon.",
    "url": "https://finnhub.io/api/news?id=8edc4e44a6b8ed7335c5b97faa4f30da8ec3d3eea4c5a21c5633e9636cb270e7",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752786280,
      "headline": "Stocks to Watch Recap: TSMC, United Airlines, GE Aerospace, Lucid",
      "id": 136005483,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "↗️ TSMC (TSM): The world's largest contract chip maker delivered a record profit last quarter and said it was speeding up its expansion in Arizona. Its American depositary receipts rallied 4% Thursday afternoon.",
      "url": "https://finnhub.io/api/news?id=8edc4e44a6b8ed7335c5b97faa4f30da8ec3d3eea4c5a21c5633e9636cb270e7"
    }
  },
  {
    "ts": null,
    "headline": "GSK stock falls after FDA panel rejects blood cancer drug Blenrep",
    "summary": "Investing.com -- GSK Plc (NYSE:GSK) stock fell 5% after a U.S. Food and Drug Administration advisory panel voted against recommending approval for its blood cancer drug Blenrep, citing concerns that risks outweigh benefits.",
    "url": "https://finnhub.io/api/news?id=01373882022b6cef9264e65fc23fd4839e7c0ef228f95da7221a58a7e2b5014e",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752777449,
      "headline": "GSK stock falls after FDA panel rejects blood cancer drug Blenrep",
      "id": 135996930,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "Investing.com -- GSK Plc (NYSE:GSK) stock fell 5% after a U.S. Food and Drug Administration advisory panel voted against recommending approval for its blood cancer drug Blenrep, citing concerns that risks outweigh benefits.",
      "url": "https://finnhub.io/api/news?id=01373882022b6cef9264e65fc23fd4839e7c0ef228f95da7221a58a7e2b5014e"
    }
  },
  {
    "ts": null,
    "headline": "Ryan Richardson Departs BioNTech (BNTX), A Pillar In US$1 Billion Capital Raises",
    "summary": "BioNTech (BNTX) recently witnessed a 13.9% increase in its share price over the last quarter. This period saw significant executive changes, including the upcoming departure of Chief Strategy Officer Ryan Richardson, as well as the appointment of Ramón Zapata-Gomez as CFO, which marks an evolution in the company's leadership. Simultaneously, BioNTech's Q1 2025 earnings announcement revealed a year-over-year increase in net loss, contrasted by steady revenue guidance expectations. These...",
    "url": "https://finnhub.io/api/news?id=47738a3c968cc096786e014cd2721268760f5123724a95b3ae5041bd71e61e48",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752773877,
      "headline": "Ryan Richardson Departs BioNTech (BNTX), A Pillar In US$1 Billion Capital Raises",
      "id": 135996931,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "BioNTech (BNTX) recently witnessed a 13.9% increase in its share price over the last quarter. This period saw significant executive changes, including the upcoming departure of Chief Strategy Officer Ryan Richardson, as well as the appointment of Ramón Zapata-Gomez as CFO, which marks an evolution in the company's leadership. Simultaneously, BioNTech's Q1 2025 earnings announcement revealed a year-over-year increase in net loss, contrasted by steady revenue guidance expectations. These...",
      "url": "https://finnhub.io/api/news?id=47738a3c968cc096786e014cd2721268760f5123724a95b3ae5041bd71e61e48"
    }
  },
  {
    "ts": null,
    "headline": "Health Care Declines as Abbott Labs, Elevance Slide on Earnings - Health Care Roundup",
    "summary": "Health Care Declines as Abbott Labs, Elevance Slide on Earnings - Health Care Roundup",
    "url": "https://finnhub.io/api/news?id=1a18147d75aa248e7bcd7a883663f7453f93314a3fc4aa5cb4283b316a21294f",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752772980,
      "headline": "Health Care Declines as Abbott Labs, Elevance Slide on Earnings - Health Care Roundup",
      "id": 136002565,
      "image": "",
      "related": "BMY",
      "source": "MarketWatch",
      "summary": "Health Care Declines as Abbott Labs, Elevance Slide on Earnings - Health Care Roundup",
      "url": "https://finnhub.io/api/news?id=1a18147d75aa248e7bcd7a883663f7453f93314a3fc4aa5cb4283b316a21294f"
    }
  },
  {
    "ts": null,
    "headline": "Pfizer (PFE) Expands Patient Access With Eliquis (Apixaban) Direct Purchase Program",
    "summary": "Pfizer (PFE), in collaboration with Bristol Myers Squibb, has introduced a direct-to-patient option for Eliquis®, potentially enhancing patient access and affordability. Over the past quarter, Pfizer's share price saw an 11% increase. This move aligns with a broader market upswing, as major indexes achieved record highs. Noteworthy developments during this time included breakthroughs in clinical studies and strategic alliances, which potentially bolstered investor confidence. However, the...",
    "url": "https://finnhub.io/api/news?id=6e7e167424d6a353d4f61db9f070d2a2424252c600a2cba62bcf5ec52d2c5910",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752772888,
      "headline": "Pfizer (PFE) Expands Patient Access With Eliquis (Apixaban) Direct Purchase Program",
      "id": 135996912,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "Pfizer (PFE), in collaboration with Bristol Myers Squibb, has introduced a direct-to-patient option for Eliquis®, potentially enhancing patient access and affordability. Over the past quarter, Pfizer's share price saw an 11% increase. This move aligns with a broader market upswing, as major indexes achieved record highs. Noteworthy developments during this time included breakthroughs in clinical studies and strategic alliances, which potentially bolstered investor confidence. However, the...",
      "url": "https://finnhub.io/api/news?id=6e7e167424d6a353d4f61db9f070d2a2424252c600a2cba62bcf5ec52d2c5910"
    }
  },
  {
    "ts": null,
    "headline": "Bristol Myers Squibb Co. stock outperforms competitors on strong trading day",
    "summary": "Bristol Myers Squibb Co. stock outperforms competitors on strong trading day",
    "url": "https://finnhub.io/api/news?id=b793e507f2005fc836a1f0f283fe909d286a3188e0ae399e906c182516aa91d5",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752770400,
      "headline": "Bristol Myers Squibb Co. stock outperforms competitors on strong trading day",
      "id": 136049844,
      "image": "",
      "related": "BMY",
      "source": "MarketWatch",
      "summary": "Bristol Myers Squibb Co. stock outperforms competitors on strong trading day",
      "url": "https://finnhub.io/api/news?id=b793e507f2005fc836a1f0f283fe909d286a3188e0ae399e906c182516aa91d5"
    }
  },
  {
    "ts": null,
    "headline": "Top Midday Stories: TSMC Lifts 2025 Revenue Growth Guidance; Lucid Partners With Uber on Robotaxi Launch",
    "summary": "All three major US stock indexes were up in late-morning trading Thursday as fresh economic data and",
    "url": "https://finnhub.io/api/news?id=d94db17994f9a835e43ce79d35c3f465634ade5cf28b9e162952cbadd8ccede4",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752768222,
      "headline": "Top Midday Stories: TSMC Lifts 2025 Revenue Growth Guidance; Lucid Partners With Uber on Robotaxi Launch",
      "id": 135993315,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "All three major US stock indexes were up in late-morning trading Thursday as fresh economic data and",
      "url": "https://finnhub.io/api/news?id=d94db17994f9a835e43ce79d35c3f465634ade5cf28b9e162952cbadd8ccede4"
    }
  },
  {
    "ts": null,
    "headline": "Bristol-Myers Squibb: Morgan Stanley highlights catalyst driven idea",
    "summary": "Investing.com -- Morgan Stanley identified Bristol-Myers Squibb (NYSE:BMY) as a catalyst-driven idea ahead of a key data readout for Cobenfy in Alzheimer’s Disease Psychosis (ADP), expected in late third or early fourth quarter.",
    "url": "https://finnhub.io/api/news?id=4ebecdac29891617050e2b4e167f81f8d548f23ecd6e24f3a192fb5bab40e316",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752764793,
      "headline": "Bristol-Myers Squibb: Morgan Stanley highlights catalyst driven idea",
      "id": 135993846,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "Investing.com -- Morgan Stanley identified Bristol-Myers Squibb (NYSE:BMY) as a catalyst-driven idea ahead of a key data readout for Cobenfy in Alzheimer’s Disease Psychosis (ADP), expected in late third or early fourth quarter.",
      "url": "https://finnhub.io/api/news?id=4ebecdac29891617050e2b4e167f81f8d548f23ecd6e24f3a192fb5bab40e316"
    }
  },
  {
    "ts": null,
    "headline": "Stocks to Watch Thursday: TSMC, United Airlines, GE Aerospace, Lucid",
    "summary": "↗️ TSMC (TSM): The world's largest contract chip maker delivered a record profit last quarter and said it was speeding up its expansion in Arizona. Its American depositary receipts rallied 4% Thursday morning.",
    "url": "https://finnhub.io/api/news?id=589bd8d0085283a4d63628123402e13b4f7abefa89cd5913ef1e74ff0cde0529",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752761552,
      "headline": "Stocks to Watch Thursday: TSMC, United Airlines, GE Aerospace, Lucid",
      "id": 135993206,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "↗️ TSMC (TSM): The world's largest contract chip maker delivered a record profit last quarter and said it was speeding up its expansion in Arizona. Its American depositary receipts rallied 4% Thursday morning.",
      "url": "https://finnhub.io/api/news?id=589bd8d0085283a4d63628123402e13b4f7abefa89cd5913ef1e74ff0cde0529"
    }
  },
  {
    "ts": null,
    "headline": "Summit Therapeutics: Not Entirely Positive HARMONi Data And Partnership Rumors",
    "summary": "Summit Therapeutics' HARMONi trial data for ivonescimab showed a clinical benefit but narrowly missed statistical significance on overall survival. Learn more on SMMT stock here.",
    "url": "https://finnhub.io/api/news?id=4ba92dd27f7fc1e518633351b13a49e8e4adb201b753fbc85c83bca1cd0ac1dd",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752759645,
      "headline": "Summit Therapeutics: Not Entirely Positive HARMONi Data And Partnership Rumors",
      "id": 135995952,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/508970732/image_508970732.jpg?io=getty-c-w1536",
      "related": "BMY",
      "source": "SeekingAlpha",
      "summary": "Summit Therapeutics' HARMONi trial data for ivonescimab showed a clinical benefit but narrowly missed statistical significance on overall survival. Learn more on SMMT stock here.",
      "url": "https://finnhub.io/api/news?id=4ba92dd27f7fc1e518633351b13a49e8e4adb201b753fbc85c83bca1cd0ac1dd"
    }
  },
  {
    "ts": null,
    "headline": "Bristol Myers, Pfizer to sell blood thinner Eliquis directly to US patients",
    "summary": "(Reuters) -Bristol Myers and Pfizer said on Thursday they will start selling their blockbuster blood thinner, Eliquis, directly to cash-paying U.S. patients at a discount to its listed price as drugmakers are under pressure from the Trump administration to lower prices.  The initiative is targeted at the small percentage of patients on Eliquis who are uninsured or underinsured, and health pricing experts cautioned that the discounted price might still be too high for many of those consumers.  The program - which would bypass traditional pharmacy benefit managers and insurers - offers a roughly 43% discount from the list price, cutting the treatment's monthly cost from around $606 to $346.",
    "url": "https://finnhub.io/api/news?id=28d29858840c119eaeb2002ae400ae508470d0b5ed22d1b87f15432d3b227bbf",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752751278,
      "headline": "Bristol Myers, Pfizer to sell blood thinner Eliquis directly to US patients",
      "id": 135993665,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "(Reuters) -Bristol Myers and Pfizer said on Thursday they will start selling their blockbuster blood thinner, Eliquis, directly to cash-paying U.S. patients at a discount to its listed price as drugmakers are under pressure from the Trump administration to lower prices.  The initiative is targeted at the small percentage of patients on Eliquis who are uninsured or underinsured, and health pricing experts cautioned that the discounted price might still be too high for many of those consumers.  The program - which would bypass traditional pharmacy benefit managers and insurers - offers a roughly 43% discount from the list price, cutting the treatment's monthly cost from around $606 to $346.",
      "url": "https://finnhub.io/api/news?id=28d29858840c119eaeb2002ae400ae508470d0b5ed22d1b87f15432d3b227bbf"
    }
  },
  {
    "ts": null,
    "headline": "Bristol Myers Squibb and Pfizer Announce Direct-to-Patient Eliquis® (apixaban) Option",
    "summary": "PRINCETON, N.J., July 17, 2025--Bristol Myers Squibb and Pfizer Announce Direct-to-Patient Eliquis® (apixaban) Option",
    "url": "https://finnhub.io/api/news?id=29e625fbe52d72cd32bfc0ccd285f9cfce505a3439f50f85857f0733d6a307ec",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752749940,
      "headline": "Bristol Myers Squibb and Pfizer Announce Direct-to-Patient Eliquis® (apixaban) Option",
      "id": 135993666,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "PRINCETON, N.J., July 17, 2025--Bristol Myers Squibb and Pfizer Announce Direct-to-Patient Eliquis® (apixaban) Option",
      "url": "https://finnhub.io/api/news?id=29e625fbe52d72cd32bfc0ccd285f9cfce505a3439f50f85857f0733d6a307ec"
    }
  },
  {
    "ts": null,
    "headline": "Bristol-Myers and Pfizer to Offer Blockbuster Blood Thinner at Discount",
    "summary": "The joint venture is launching a direct-to-consumer service of Eliquis after discussions with the Trump administration.",
    "url": "https://finnhub.io/api/news?id=fc9a45262e7892e03c8412bf1e51eb5999fcd4d2e0fb991962602f950ff096b9",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752748200,
      "headline": "Bristol-Myers and Pfizer to Offer Blockbuster Blood Thinner at Discount",
      "id": 135993667,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "The joint venture is launching a direct-to-consumer service of Eliquis after discussions with the Trump administration.",
      "url": "https://finnhub.io/api/news?id=fc9a45262e7892e03c8412bf1e51eb5999fcd4d2e0fb991962602f950ff096b9"
    }
  }
]